Aptose Biosciences is a biotechnology company focused on developing novel oncology therapies to treat life-threatening cancers such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The company's approach is to utilize insights into the genetic and epigenetic profiles of certain cancers and patient populations to create targeted medicines for precision treatment based on a patient's specific gene expression signature. This strategy is intended to not only maximize efficacy but also minimize the cytotoxic side effects associated with traditional treatments. Aptose Biosciences is building a pipeline of first-in-class agents directed at dysregulated processes and signaling pathways to address the unmet needs of patients with hematologic malignancies.